Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Pfizer posts another haemophilia hit
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.